Table 1

Post-hoc characterization of leukocyte differentiation markers
Phenotype	Intended designation

1. CD45^loCD34⁺	ISHAGE protocol
2. Lin^-CD45^loCD34⁺	Hematopoietic progenitors
3. Lin^-CD45^loCD34⁺CD133⁺CD117⁺	Hematopoietic stem cells*
4. Lin^-CD45^-CD133⁺CD31⁺CD144⁺KDR⁺	Endothelial precursor*
5. Lin^-CD45^-CD133^-CD31⁺CD144⁺KDR⁺	Endothelial cell*
6. CD45⁺CD10⁺CD33⁺HLA-DR^-CD45RA^-	Myeloid precursor*
7. CD45⁺CD10⁺CD33^-HLA-DR⁺CD45RA⁺	Lymphoid precursor*
8. CD45^-CD133⁺CD146⁺CD144⁺CD166⁺	Mesenchymal progenitor*
9. CD45^-CD133^-CD146⁺CD73⁺CD166⁺	Mesenchymal cell*
10. CD45⁺CD10⁺CD34⁺CD19^-CD38^-TdT⁺IgM^-	pre-pro-B intermediary
10.1. CD45⁺CD10⁺CD34⁺CD19⁺CD38^-TdT⁺IgM^-	pro-B/pre-B I intermediary
10.2. CD45⁺CD10⁺CD34^-CD19⁺CD38^-TdT^-IgM^-	Pre-B II intermediary
10.3. CD45⁺CD10^-CD34^-CD19⁺CD38⁺TdT^-IgM⁺CD24^hi	Immature B LΦ
10.4. CD45⁺CD10^-CD34^-CD19⁺CD38⁺TdT^-IgM⁺	Naïve B LΦ
10.5. CD45⁺CD10^-CD34^-CD19⁺CD38⁺TdT^-IgM⁺CD24^loCD69⁺	Mature B LΦ
11. CD45⁺CD34⁺CD38^-CD1a^-CD3^-CD4^-CD8^-	LΦ-T DN1
11.1. CD45⁺CD34⁺CD38⁺CD1a^-CD3^-CD4^-CD8^-	LΦ-T DN2
11.2. CD45⁺CD34⁺CD38⁺CD1a⁺CD3^-CD4^-CD8^-	LΦ-T DN3
11.3. CD45⁺CD34⁺CD38⁺CD1a⁺CD3^loCD4⁺CD8^-	LΦ-T DN4-ISP
11.4. CD45⁺CD34⁺CD38⁺CD3^-CD4⁺CD8⁺	LΦ-T DP
11.5. CD45⁺CD34⁺CD38⁺CD3⁺CD4⁺CD8⁺	LΦ-T DP-CD3
12. CD45⁺CD34⁺CD3⁺CD4⁺CD8^-	LΦ-T CD4
13. CD45⁺CD34⁺CD3⁺CD4^-CD8⁺	LΦ-T CD8
14. CD45⁺CD122⁺CD56⁺CD3^-	NK cells
15. CD45⁺CD66acde⁺	Neutrophils/Basophils
16. CD45⁺CD41a⁺	Megakaryocytes
17. CD45⁺CD66acde^-CD41a^-CD14⁺CD16⁺	Monocytes/Macrophages

*The intended designation to some phenotypes will be more deeply explored with additional markers like CD117, CD31, CD105, CD106, CD166 and others of interest. Besides, cell subpopulations also will be sorted to perform supplementary function assays.
Dohmann et al. Trials 2008 9:41 doi:10.1186/1745-6215-9-41